[Skip to Content]
[Skip to Content Landing]
October 1996

Use of Mitomycin C in the Treatment of Conjunctival Primary Acquired Melanosis With Atypia

Author Affiliations

From the Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel. The authors have no proprietary interest in the development or marketing of this or a competing drug.

Arch Ophthalmol. 1996;114(10):1261-1264. doi:10.1001/archopht.1996.01100140461020

A patient who had primary acquired melanosis with marked atypia shown on histological studies received topical 0.02% mitomycin C for 2 weeks and 0.04% mitomycin C for an additional 2 weeks. Conjunctival biopsy specimens were obtained to evaluate the efficacy of the treatment. After the first course of mitomycin C administration, some decrease of conjunctival pigmentation was seen, and histological studies disclosed a lower degree of atypia. After the second application of mitomycin C, the pigmentation disappeared except for one small spot that contained only a few typical melanocytes on histological study. The clinical findings did not change during 7 months of follow-up. No adverse reactions to topical mitomycin C occurred except for mild conjunctival hyperemia at the end of the courses of treatment. Administration of topical mitomycin C may be an effective medical treatment for primary acquired melanosis with atypia.